PDPHF (Egetis Therapeutics AB) Cyclically Adjusted PB Ratio: (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PDPHF Egetis Therapeutics AB PDPHF
67 GF Score
Price $0.64
GF Value $0.51
! 7 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Egetis Therapeutics AB  (OTCPK:PDPHF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Egetis Therapeutics AB Cyclically Adjusted PB Ratio Related Terms


Egetis Therapeutics AB Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Egetis Therapeutics AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB Cyclically Adjusted PB Ratio Chart

Egetis Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.76 1.82 1.37 1.75 1.39

Egetis Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 1.17 1.44 1.39 1.44

PDPHF vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Egetis Therapeutics AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Cyclically Adjusted PB Ratio falls into.


PDPHF
67GF Score
Egetis Therapeutics AB PDPHF
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egetis Therapeutics AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Egetis Therapeutics AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Egetis Therapeutics AB's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.067/133.5600*133.5600
=0.067

Current CPI (Mar. 2026) = 133.5600.

Egetis Therapeutics AB Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.112 101.019 0.148
201609 0.079 101.138 0.104
201612 0.786 102.022 1.029
201703 0.786 102.022 1.029
201706 0.776 102.752 1.009
201709 0.778 103.279 1.006
201712 0.672 103.793 0.865
201803 0.649 103.962 0.834
201806 0.548 104.875 0.698
201809 0.502 105.679 0.634
201812 0.451 105.912 0.569
201903 0.485 105.886 0.612
201906 0.538 106.742 0.673
201909 0.466 107.214 0.581
201912 0.438 107.766 0.543
202003 0.347 106.563 0.435
202006 0.301 107.498 0.374
202009 0.270 107.635 0.335
202012 0.419 108.296 0.517
202103 0.397 108.360 0.489
202106 0.382 108.928 0.468
202109 0.357 110.338 0.432
202112 0.322 112.486 0.382
202203 0.290 114.825 0.337
202206 0.295 118.384 0.333
202209 0.249 122.296 0.272
202212 0.227 126.365 0.240
202303 0.240 127.042 0.252
202306 0.205 129.407 0.212
202309 0.169 130.224 0.173
202312 0.182 131.912 0.184
202403 0.155 132.205 0.157
202406 0.131 132.716 0.132
202409 0.106 132.304 0.107
202412 0.125 132.987 0.126
202503 0.119 132.825 0.120
202506 0.103 133.699 0.103
202509 0.082 133.480 0.082
202512 0.092 133.390 0.092
202603 0.067 133.560 0.067

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of $0.64 is trading 24.6% above its estimated GF Value™ of $0.51.

Key valuation signals for PDPHF:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $0.51 vs. price of $0.64 (24.6% above fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
67GF Score

Get the complete analysis for PDPHF

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price
$0.51
GF Value